EMA Authorised: Mekinist (trametinib) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Mekinist (trametinib) for melanoma; the marketing authorisation holder is Novartis Europharm Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MEKINIST (trametinib)

Snippet

Status: Authorised. Therapeutic area: Melanoma. MAH: Novartis Europharm Limited. Decision date: 13/11/2025